RussellZeligSzmulewitzMD

Oncology • Chicago, IL

Genitourinary Oncology

Associate Professor of Medicine, University of Chicago Medicine

Join to view full profile

Dr. Szmulewitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Szmulewitz's full profile

Already have an account?

Office
5841 S. MARYLAND
M/C 2115
Chicago, IL 60637
Phone+1 773-702-7609

Fax+1 773-702-3163

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2006 - 2009
NYU Grossman School of MedicineResidency, Internal Medicine, 2003 - 2006
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2003

Certifications & Licensure

IL State Medical License 2006 - 2026
NY State Medical License 2005 - 2007
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Pazopanib, Docetaxel, Prednisone Prostate Start of enrollment: 2011 Jun 01
Completed
Phase 1
The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 1
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 2
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer Start of enrollment: 2012 May 01
Completed
Phase 2
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer Start of enrollment: 2013 Dec 13
Completed
Phase 1, Phase 2
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer Start of enrollment: 2018 Oct 23
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma.
Daniel Huang, Connor Lynch, Lucas M Serra, Randy F Sweis, Paul J Chang
Clinical and Translational Radiation Oncology. 2024-11-01
2 citations
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, Nabil Adra, Jingsong Zhang
Clinical Cancer Research. 2024-10-01
Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an A...
Greeshma Rajeev-Kumar, Sean P Pitroda, Russell Z Szmulewitz, Ted Skolarus, Scott E Eggener
Clinical Genitourinary Cancer. 2024-08-01

Press Mentions

Benefits of PSMA-PET for High-risk/Advanced Prostate Cancer: Part 2August 26th, 2022
Benefits of PSMA-PET for High-risk/Advanced Prostate Cancer: Part 1August 26th, 2022
Taking a Standard Prostate Cancer Drug with Food Boosts Impact, Lowers CostMarch 30th, 2018
Join now to see all